Littérature scientifique sur le sujet « Optimal Cytoreduction »

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Optimal Cytoreduction ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "Optimal Cytoreduction"

1

Memarzadeh, S., S. B. Lee, J. S. Berek, and R. Farias-Eisner. "CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer." International Journal of Gynecologic Cancer 13, no. 2 (2003): 120–24. http://dx.doi.org/10.1136/ijgc-00009577-200303000-00003.

Texte intégral
Résumé :
The utility of preoperative CA125 to predict optimal primary tumor cytoreduction in patients with advanced (stages IIIC and IV) epithelial ovarian cancer is controversial. In this paper, we retrospectively review patients with stage IIIC and IV epithelial ovarian cancer who underwent primary cytoreductive surgery from 1989 to 2001. Ninety-nine patients were identified and included in the analysis. All patients had preoperative CA125 levels measured. Operative and pathology reports were reviewed. Optimal cytoreduction was defined as largest volume of residual disease < 1 cm in maximal dimens
Styles APA, Harvard, Vancouver, ISO, etc.
2

Lūža, Tomas, Agnė Ožalinskaitė, and Vilius Rudaitis. "The rate and role of diaphragmatic peritonectomy in optimal cytoreduction in patients with advanced stage ovarian cancer: a prospective study of 100 patients." Acta medica Lituanica 21, no. 1 (2014): 1–7. http://dx.doi.org/10.6001/actamedica.v21i1.2882.

Texte intégral
Résumé :
Background. Diaphragmatic peritoneal metastasis by advanced epi­thelial ovarian cancer is a very common holdback precluding optimal cytoreduction. The aim of this study was to determine the rate of dia­phragmatic peritonectomy during optimal cytoreductive surgery and its role in postoperative morbidity and survival in patients with advanced ovarian cancer. Materials and methods. 100 consecutive patients with advanced epithelial ovarian cancer underwent cytoreductive surgery and were followed up prospectively (January 2009 – March 2014). Characteristics of surgery, rate of diaphragmatic periton
Styles APA, Harvard, Vancouver, ISO, etc.
3

A, Camargo, Bianchi F, Habich D, and Castaño R. "The fundamental role of the exploration of the upper abdomen in ovarian cancer surgery." Obstetrics & Gynecology International Journal 12, no. 5 (2021): 337–42. http://dx.doi.org/10.15406/ogij.2021.12.00603.

Texte intégral
Résumé :
Purpose: Several studies have shown the benefit of cytoreductive surgery in advanced disease, that is why the residual tumor has prognostic value. Our primary objective was to determine the frequency of involvement of the upper abdomen, defined as the extension of the disease above the transverse colon (diaphragm, spleen, gallbladder, stomach, hepatic parenchyma, hepatic capsule, minor omentum, hepatic ilium, pancreas). Our secondary objective was to analyze the possibilities of complete cytoreduction in these patients, their complications and results. Materials and methods: We retrospectively
Styles APA, Harvard, Vancouver, ISO, etc.
4

Abdullaev, A. G., М. M. Davydov, and N. A. Коzlov. "CHALLENGES IN CHOICE OF THE TREATMENT STRATEGY FOR PATIENTS WITH RECURRENT PSEUDOMYXOMA PERITONEI." Siberian journal of oncology 18, no. 3 (2019): 78–83. http://dx.doi.org/10.21294/1814-4861-2019-18-3-78-83.

Texte intégral
Résumé :
Pseudomixoma peritonei is a rare type of peritoneal carcinomatosis accompanied by accumulation of mucus and high recurrence rate and in some cases complicated with intestinal obstruction. In the last 10–15 years, there has been observed a significant improvement in overall survival of patients with recurrent pseudomyxoma, who underwent cytoreductive surgery in combination with intraperitoneal chemotherapy. However, the frequency of recurrences of peritoneal pseudomyxoma after optimal cytoreduction can reach 80–90 % in the first 2 years.The purpose of the study was to analyze the results of com
Styles APA, Harvard, Vancouver, ISO, etc.
5

Turan, Taner, Tolga Tasci, Alper Karalok, et al. "Salvage Cytoreductive Surgery for Recurrent Endometrial Cancer." International Journal of Gynecologic Cancer 25, no. 9 (2015): 1623–32. http://dx.doi.org/10.1097/igc.0000000000000543.

Texte intégral
Résumé :
ObjectiveThe aim of this study was to determine the effect of salvage cytoreductive surgery (SCS) on overall survival (OS) among patients with recurrent endometrial cancer and if there is any predictor for residual tumor status.MethodsBetween January 1993 and May 2013, data of 34 patients who had SCS for recurrent endometrial cancer were retrospectively analyzed. Overall survival was determined from SCS to last follow-up.ResultsThe surgical procedure was local excision without laparotomy in 12 patients, and optimal cytoreduction (no visible disease) was achieved in 24 of 34 patients. There wer
Styles APA, Harvard, Vancouver, ISO, etc.
6

Roberts, William S. "Cytoreductive Surgery in Ovarian Cancer: Why, When, and How?" Cancer Control 3, no. 2 (1996): 130–36. http://dx.doi.org/10.1177/107327489600300205.

Texte intégral
Résumé :
Retrospective evidence supports the value of optimal cytoreductive surgery in the initial therapy of patients with advanced ovarian cancer. Specialized procedures, including radical pelvic surgery, bowel resection, and diaphragm resections, are frequently necessary to accomplish optimal cytoreduction. Cytoreduction and total gross tumor removal are possible more frequently with new surgical instruments such as the Cavitron ultrasonic surgical aspirator and argon beam laser. Pelvic and periaortic lymph node resection is an important aspect of cytoreductive surgery, and systematic removal of gro
Styles APA, Harvard, Vancouver, ISO, etc.
7

Abdalla Ahmed, Shimaa, Hisham Abou-Taleb, Noha Ali, and Dalia M. Badary. "Accuracy of radiologic– laparoscopic peritoneal carcinomatosis categorization in the prediction of surgical outcome." British Journal of Radiology 92, no. 1100 (2019): 20190163. http://dx.doi.org/10.1259/bjr.20190163.

Texte intégral
Résumé :
Objective: To evaluate the agreement between multiple detector CT (MDCT) and laparoscopy in the preoperative categorization of peritoneal carcinomatosis, and to determine the impact of this categorization on the prediction of cytoreduction status. Methods: This prospective study included 80 consecutive females with primary ovarian cancer eligible for cytoreductive surgery (CRS). MDCT and diagnostic laparoscopy were performed prior to surgery for assessment of peritoneal carcinomatosis extent. Based on PCI (peritoneal cancer index) score, carcinomatosis was categorized into three groups. Catego
Styles APA, Harvard, Vancouver, ISO, etc.
8

Cardillo, Nicholas, Eric J. Devor, Silvana Pedra Nobre, et al. "Integrated Clinical and Genomic Models to Predict Optimal Cytoreduction in High-Grade Serous Ovarian Cancer." Cancers 14, no. 14 (2022): 3554. http://dx.doi.org/10.3390/cancers14143554.

Texte intégral
Résumé :
Advanced high-grade serous (HGSC) ovarian cancer is treated with either primary surgery followed by chemotherapy or neoadjuvant chemotherapy followed by interval surgery. The decision to proceed with surgery primarily or after chemotherapy is based on a surgeon’s clinical assessment and prediction of an optimal outcome. Optimal and complete cytoreductive surgery are correlated with improved overall survival. This clinical assessment results in an optimal surgery approximately 70% of the time. We hypothesize that this prediction can be improved by using biological tumor data to predict optimal
Styles APA, Harvard, Vancouver, ISO, etc.
9

Abdallah, Reem, Hye Sook Chon, Nadim Bou Zgheib, et al. "Prediction of Optimal Cytoreductive Surgery of Serous Ovarian Cancer With Gene Expression Data." International Journal of Gynecologic Cancer 25, no. 6 (2015): 1000–1009. http://dx.doi.org/10.1097/igc.0000000000000449.

Texte intégral
Résumé :
ObjectivesCytoreductive surgery is the cornerstone of ovarian cancer (OVCA) treatment. Detractors of initial maximal surgical effort argue that aggressive tumor biology will dictate survival, not the surgical effort. We investigated the role of biology in achieving optimal cytoreduction in serous OVCA using microarray gene expression analysis.MethodsFor the initial model, we used a gene expression signature from a microarray expression analysis of 124 women with serous OVCA, defining optimal cytoreduction as removal of all disease greater than 1 cm (with 64 women having optimal and 60 suboptim
Styles APA, Harvard, Vancouver, ISO, etc.
10

Arits, A. H. M. M., J. E. G. M. Stoot, A. A. M. Botterweck, F. J. M. E. Roumen, and A. C. Voogd. "Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer." International Journal of Gynecologic Cancer 18, no. 4 (2008): 621–28. http://dx.doi.org/10.1136/ijgc-00009577-200807000-00004.

Texte intégral
Résumé :
The objective is to assess the ability of preoperative serum CA125 levels to identify patients at high risk of suboptimal cytoreductive surgery for epithelial ovarian cancer (EOC). One hundred and thirty-two women diagnosed with EOC between 1998 and 2004, who had serum CA125 levels measured preoperatively and received primary cytoreductive surgery, were retrospectively evaluated. The value of CA125 and patient and disease characteristics to predict suboptimal cytoreduction were determined, and a prognostic scoring system, based on statistically significant variables, was created. Optimal cytor
Styles APA, Harvard, Vancouver, ISO, etc.
Plus de sources

Thèses sur le sujet "Optimal Cytoreduction"

1

PEIRETTI, MICHELE. "Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. single institution experience." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2010. http://hdl.handle.net/10281/8049.

Texte intégral
Résumé :
Objective. The objective of the present study was to determinate the impact of maximal cytoreductive surgery on progression free survival, overall survival rates and morbidity, in patients with advanced epithelial ovarian or fallopian tube cancer (stage IIIC-IV) treated in a referral cancer center. Methods. After obtaining Institutional Review Board approval, we reviewed all medical records of patients with stage IIIC–IV epithelial ovarian cancer who were managed at our institution between January 2001 and December 2008. Individual records were reviewed and the following information collected
Styles APA, Harvard, Vancouver, ISO, etc.

Chapitres de livres sur le sujet "Optimal Cytoreduction"

1

Morton, Molly, Tiffany Y. Sia, Laura M. Chambers, Roberto Vargas, and Robert Debernardo. "Is there a Role for Intraperitoneal Chemotherapy after Optimal Cytoreduction of Ovarian Cancer?" In 50 Big Debates in Gynecologic Oncology. Cambridge University Press, 2023. http://dx.doi.org/10.1017/9781108935579.029.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Secord, Angeles Alvarez, and Laura J. Havrilesky. "Is there a Role for Intraperitoneal Chemotherapy after Optimal Cytoreduction of Ovarian Cancer?" In 50 Big Debates in Gynecologic Oncology. Cambridge University Press, 2023. http://dx.doi.org/10.1017/9781108935579.030.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

Elena Buruiana, Felicia, Lamiese Ismail, Federico Ferrari, and Hooman Soleymani Majd. "The Role of Ultra-Radical Surgery in the Management of Advanced Ovarian Cancer: State or Art." In Ovarian Cancer - Updates in Tumour Biology and Therapeutics [Working Title]. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.97638.

Texte intégral
Résumé :
The ovarian cancer, also known as “silent killer”, has remained the most lethal gynaecological malignancy. The single independent risk factor linked with improved survival is maximum cytoreductive effort resulting in no macroscopic residual disease. This could be gained through ultra-radical surgery which demands tackling significant tumour burden in pelvis, lower and upper abdomen which usually constitutes bowel resection, liver mobilisation, ancillary cholecystectomy, extensive peritonectomy, diaphragmatic resection, splenectomy, resection of enlarged pelvic, paraaortic, and rarely cardio-ph
Styles APA, Harvard, Vancouver, ISO, etc.
4

Blanc-Durand, Félix, Amandine Maulard, and Patricia Pautier. "Should Secondary Cytoreductive Surgery be Offered to all Patients that are Surgical Candidates with Optimally Resectable Recurrent Uterine Leiomyosarcoma?" In 50 Big Debates in Gynecologic Oncology. Cambridge University Press, 2023. http://dx.doi.org/10.1017/9781108935579.082.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
5

Aletti, Giovanni. "Should Secondary Cytoreductive Surgery be Offered to all Patients that are Surgical Candidates with Optimally Resectable Recurrent Uterine Leiomyosarcoma?" In 50 Big Debates in Gynecologic Oncology. Cambridge University Press, 2023. http://dx.doi.org/10.1017/9781108935579.081.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.

Actes de conférences sur le sujet "Optimal Cytoreduction"

1

Mukhopadhyay, Asima, Basumita Chakraborti, Anik Ghosh, and Jaydip Bhaumik. "Implementing quality indicators for cytoreductive surgery in ovarian cancer: Experience from a tertiary referral center in Eastern India." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685291.

Texte intégral
Résumé :
Background: Debate continues whether primary surgery or neo-adjuvant chemotherapy (NACT) or primary debulking surgery (PDS) should be offered in advanced epithelial ovarian cancer as frontline therapy. Since 2015, there has been a paradigm shift at Tata Medical center, whereas increasing number of patients are being offered PDS and a quality improvement programme was initiated. Recently, ESGO in October 2015 has published a document indicating 10 quality indicators for cytoreductive surgery in advanced ovarian cancer surgery. Aim: We compared our performance against all 10 quality indicators.
Styles APA, Harvard, Vancouver, ISO, etc.
2

Bora, Rashmi Rekha. "Modified posterior pelvic exenteration and rectosigmoid anastomosis for advance epithelial ovarian cancer: A safe cytoreductive procedure." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685294.

Texte intégral
Résumé :
Introduction: Surgery plays an important role in the management of advanced stage ovarian cancer and is complex involving surgical procedures including peritonectomy, splenectomy, diaphragmatic stripping, retroperitoneal lymph node dissection and bowel resection including resection of recto-sigmoid. Objective: To assess the safety and efficacy of the patients undergoing modified posterior pelvic exenteration and rectosigmoid anastomosis achieving in optimal cytoreduction. Methods: Between June 2011 and June 2014 a total of 100 patients underwent surgical cytoreduction for advanced epithelial o
Styles APA, Harvard, Vancouver, ISO, etc.
3

Kumar, Siva. "Neoadjuvant chemotherapy in epithelial ovarian cancer: Largest single institute experience." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685312.

Texte intégral
Résumé :
Purpose: Neoadjuvant chemotherapy followed by interval debulking surgery (IDS) is an alternative treatment option, compared to the current standard of care primary debulking surgery for treating advanced epithelial ovarian cancer (EOC). We present our institute experience of neoadjuvant chemotherapy strategy in the management of EOC which is one of the largest single institute experience. Methods: This is a retrospective analysis of patients with epithelial ovarian cancer who were treated in our institute between 2000 and 2006. Patient with advanced disease by clinical and imaging were treated
Styles APA, Harvard, Vancouver, ISO, etc.
4

Kumar, Siva. "Neoadjuvant chemotherapy in epithelial ovarian cancer: Largest single institute experience." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685313.

Texte intégral
Résumé :
Purpose: Neoadjuvant chemotherapy followed by interval debulking surgery (IDS) is an alternative treatment option, compared to the current standard of care primary debulking surgery for treating advanced epithelial ovarian cancer (EOC). We present our institute experience of neoadjuvant chemotherapy strategy in the management of EOC which is one of the largest single institute experience. Methods: This is a retrospective analysis of patients with epithelial ovarian cancer who were treated in our institute between 2000 and 2006. Patient with advanced disease by clinical and imaging were treated
Styles APA, Harvard, Vancouver, ISO, etc.
5

Nakka, Thejeswar, Prasanth Ganesan, Luxitaa Goenka, et al. "Epithelial Ovarian Cancer: Real-World Outcomes." In Annual Conference of Indian Society of Medical and Paediatric Oncology (ISMPO). Thieme Medical and Scientific Publishers Pvt. Ltd., 2021. http://dx.doi.org/10.1055/s-0041-1735369.

Texte intégral
Résumé :
Abstract Introduction Ovarian cancer is the third most common cancer and the second most common cause of death among gynecological cancers in Indian women. Ovarian cancer is heterogeneous, among them, epithelial ovarian cancer (EOC) is the most common. Primary cytoreductive surgery along with six to eight cycles of a combination of platinum and taxanes chemotherapy is the cornerstone of first-line treatment in EOC. This study was done to find clinicopathological factors affecting survival outcomes with first-line therapy in EOC in a real-world setting. Objectives This study was aimed to find f
Styles APA, Harvard, Vancouver, ISO, etc.
6

Kumar, Neha, Amita Maheshwari, Sudeep Gupta, et al. "Retrospective analysis of surgical outcomes and survival in women with advanced ovarian cancer undergoing interval debulking surgery." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685404.

Texte intégral
Résumé :
Introduction: Both primary (PDS) and interval debulking surgery (IDS) have reported similar progression free survival (PFS) and overall survival (OS) rates in various studies. Complete resection of all macroscopic disease is the strongest independent variable in predicting survival in both groups. Objective: To evaluate the demographics, surgical outcomes and survival in women with advanced ovarian cancer undergoing IDS. Methods: All women with Stage IIIC or Stage IV epithelial ovarian or primary peritoneal cancer, registered at our institution from January 2010 to December 2010, who were trea
Styles APA, Harvard, Vancouver, ISO, etc.
7

Candotti, Giorgio, Alice Bergamini, Raffaella Cioffi, et al. "2022-RA-1072-ESGO Optimal cytoreduction for advanced epithelial ovarian cancer: non invasive predictive factors." In ESGO 2022 Congress. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/ijgc-2022-esgo.625.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
8

Maricic, S., A. Mandic, N. Prvulovic Bunovic, S. Stojanovic, I. Stojic, and N. Stanulovic. "EPV222/#603 Radiological response to neoadjuvant chemotherapy as indicator of optimal cytoreduction in advanced ovarian cancer." In IGCS 2021 Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2021. http://dx.doi.org/10.1136/ijgc-2021-igcs.293.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
9

Feuer, G., I. Mousavi, and N. Lakhi. "SF007/#206 A systematic approach for achieving optimal cytoreduction of locally advanced endometrial cancer by a robotic approach." In IGCS 2021 Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2021. http://dx.doi.org/10.1136/ijgc-2021-igcs.51.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
10

Altieri, Alfonso, Andrea Ungredda, Giuseppina Fais, et al. "SF010/#1156 Laparoscopic tertiary optimal cytoreduction in recurrent ovarian cancer: safety and feasibility of a BRCA mutated patient." In IGCS 2024 Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2024. http://dx.doi.org/10.1136/ijgc-2024-igcs.634.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!